2002 - Fellow of the American Association for the Advancement of Science (AAAS)
In her works, Elise C. Kohn performs multidisciplinary study on Cancer and Pathology. She connects Pathology with Cancer in her research. As part of her studies on Internal medicine, she frequently links adjacent subjects like Toxicity. She regularly ties together related areas like Internal medicine in her Toxicity studies. Elise C. Kohn performs multidisciplinary study in Gene and Proteomics in her work. Elise C. Kohn performs integrative Proteomics and Gene research in her work. In her work, Elise C. Kohn performs multidisciplinary research in Biochemistry and Genetics. In her papers, Elise C. Kohn integrates diverse fields, such as Genetics and Biochemistry. She integrates many fields in her works, including Ovarian cancer and BRCA mutation.
Elise C. Kohn conducts interdisciplinary study in the fields of Internal medicine and Gastroenterology through her works. Elise C. Kohn integrates Gastroenterology with Internal medicine in her study. While working in this field, she studies both Cancer and Clinical trial. Elise C. Kohn performs multidisciplinary study in the fields of Clinical trial and Cancer via her papers. In her research, she performs multidisciplinary study on Ovarian cancer and Chemotherapy. She connects Chemotherapy with Ovarian cancer in her research. She connects Oncology with Pathology in her study. She conducts interdisciplinary study in the fields of Pathology and Oncology through her works. Elise C. Kohn connects Biochemistry with Cell biology in her study.
As part of her research on Ovarian cancer, studies on BRCA mutation and Gynecologic cancer are part of the effort. Elise C. Kohn frequently studies issues relating to Ovarian cancer and Gynecologic cancer. Her research on Cancer frequently links to adjacent areas such as Immunotherapy. Her study deals with a combination of Internal medicine and Gynecology. Elise C. Kohn combines Oncology and Intensive care medicine in her research. Elise C. Kohn undertakes multidisciplinary studies into Intensive care medicine and Oncology in her work. Her Clinical trial study frequently draws connections between related disciplines such as Bioinformatics. Her research is interdisciplinary, bridging the disciplines of Clinical trial and Bioinformatics. Borrowing concepts from Disease, Elise C. Kohn weaves in ideas under Gene.
Her Carcinogenesis study spans across into areas like Cell cycle and Cancer research. Elise C. Kohn integrates many fields, such as Cell cycle and Carcinogenesis, in her works. As part of her studies on Cancer research, she often connects relevant areas like Tumor microenvironment. Her work blends Cancer and Immunology studies together. Immunology connects with themes related to Tumor microenvironment in her study. Elise C. Kohn integrates many fields in her works, including Gene and Bioinformatics. In her work, Elise C. Kohn performs multidisciplinary research in Bioinformatics and Gene. Elise C. Kohn performs multidisciplinary studies into Oncology and Gynecology in her work. In her work, Elise C. Kohn performs multidisciplinary research in Gynecology and Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The microenvironment of the tumour-host interface
Lance A. Liotta;Elise C. Kohn.
Serum Proteomic Patterns for Detection of Prostate Cancer
Emanuel F. Petricoin;David K. Ornstein;Cloud P. Paweletz;Ali Ardekani.
Journal of the National Cancer Institute (2002)
The MAPK pathway across different malignancies: a new perspective.
Mauricio Burotto;Victoria L. Chiou;Jung-Min Lee;Elise C. Kohn.
Molecular Insights into Cancer Invasion: Strategies for Prevention and Intervention
Elise C. Kohn;Lance A. Liotta.
Cancer Research (1995)
Clinical proteomics: translating benchside promise into bedside reality
Emanuel F. Petricoin;Kathryn C. Zoon;Elise C. Kohn;J. Carl Barrett.
Nature Reviews Drug Discovery (2002)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu;William T. Barry;Michael Birrer;Jung Min Lee.
Lancet Oncology (2014)
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer
Monica Brown Jones;Henry Krutzsch;Hungjun Shu;Yingming Zhao.
Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
Nilofer S. Azad;Edwin M. Posadas;Virginia E. Kwitkowski;Seth M. Steinberg.
Journal of Clinical Oncology (2008)
Angiogenesis: role of calcium-mediated signal transduction.
Elise C. Kohn;Riccardo Alessandro;Joseph Spoonster;Robert P. Wersto.
Proceedings of the National Academy of Sciences of the United States of America (1995)
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee Jm;Ledermann Ja;Kohn Ec.
Annals of Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: